MEDPACE HOLDINGS INC (MEDP) Stock Fundamental Analysis
USA - NASDAQ:MEDP - US58506Q1094 - Common Stock
543.89 USD
-0.52 (-0.1%)
Overall MEDP gets a fundamental rating of 7 out of 10. We evaluated MEDP against 57 industry peers in the Life Sciences Tools & Services industry. MEDP gets an excellent profitability rating and is at the same time showing great financial health properties. MEDP is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make MEDP a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
MEDP had positive earnings in the past year.
In the past year MEDP had a positive cash flow from operations.
In the past 5 years MEDP has always been profitable.
Each year in the past 5 years MEDP had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 26.61%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
MEDP's Return On Equity of 242.70% is amongst the best of the industry. MEDP outperforms 100.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 115.03%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for MEDP is significantly above the industry average of 14.93%.
The last Return On Invested Capital (115.03%) for MEDP is above the 3 year average (38.75%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.61% | ||
| ROE | 242.7% | ||
| ROIC | 115.03% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1.3 Margins
MEDP's Profit Margin of 18.74% is amongst the best of the industry. MEDP outperforms 92.98% of its industry peers.
MEDP's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 21.40%, MEDP belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
MEDP's Operating Margin has improved in the last couple of years.
With a Gross Margin value of 31.62%, MEDP is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
MEDP's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.4% | ||
| PM (TTM) | 18.74% | ||
| GM | 31.62% |
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MEDP is creating value.
MEDP has less shares outstanding than it did 1 year ago.
The number of shares outstanding for MEDP has been reduced compared to 5 years ago.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
MEDP has an Altman-Z score of 7.82. This indicates that MEDP is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.82, MEDP belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 7.82 |
ROIC/WACC10.99
WACC10.47%
2.3 Liquidity
MEDP has a Current Ratio of 0.43. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MEDP's Current ratio of 0.43 is on the low side compared to the rest of the industry. MEDP is outperformed by 96.49% of its industry peers.
A Quick Ratio of 0.43 indicates that MEDP may have some problems paying its short term obligations.
MEDP's Quick ratio of 0.43 is on the low side compared to the rest of the industry. MEDP is outperformed by 94.74% of its industry peers.
MEDP does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.43 | ||
| Quick Ratio | 0.43 |
3. Growth
3.1 Past
MEDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.53%, which is quite impressive.
MEDP shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 33.22% yearly.
The Revenue has grown by 9.94% in the past year. This is quite good.
The Revenue has been growing by 19.62% on average over the past years. This is quite good.
EPS 1Y (TTM)26.53%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%12.73%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%14.24%
3.2 Future
The Earnings Per Share is expected to grow by 10.11% on average over the next years. This is quite good.
MEDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.93% yearly.
EPS Next Y13.52%
EPS Next 2Y11.72%
EPS Next 3Y11.39%
EPS Next 5Y10.11%
Revenue Next Year16.85%
Revenue Next 2Y12.67%
Revenue Next 3Y11.46%
Revenue Next 5Y10.93%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 40.44, which means the current valuation is very expensive for MEDP.
Compared to the rest of the industry, the Price/Earnings ratio of MEDP indicates a somewhat cheap valuation: MEDP is cheaper than 61.40% of the companies listed in the same industry.
MEDP is valuated rather expensively when we compare the Price/Earnings ratio to 27.69, which is the current average of the S&P500 Index.
MEDP is valuated quite expensively with a Price/Forward Earnings ratio of 34.50.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MEDP indicates a somewhat cheap valuation: MEDP is cheaper than 64.91% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of MEDP to the average of the S&P500 Index (23.18), we can say MEDP is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.44 | ||
| Fwd PE | 34.5 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as MEDP.
80.70% of the companies in the same industry are more expensive than MEDP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.35 | ||
| EV/EBITDA | 30.1 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDP does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of MEDP may justify a higher PE ratio.
PEG (NY)2.99
PEG (5Y)1.22
EPS Next 2Y11.72%
EPS Next 3Y11.39%
5. Dividend
5.1 Amount
MEDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:MEDP (10/21/2025, 2:51:42 PM)
543.89
-0.52 (-0.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners94.93%
Inst Owner Change0.24%
Ins Owners0.54%
Ins Owner Change-1.26%
Market Cap15.28B
Analysts52.94
Price Target433.15 (-20.36%)
Short Float %9.86%
Short Ratio4.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.2%
Min EPS beat(2)2.57%
Max EPS beat(2)17.84%
EPS beat(4)4
Avg EPS beat(4)12.05%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.09%
EPS beat(12)11
Avg EPS beat(12)14.32%
EPS beat(16)15
Avg EPS beat(16)14.6%
Revenue beat(2)2
Avg Revenue beat(2)6.91%
Min Revenue beat(2)4.04%
Max Revenue beat(2)9.78%
Revenue beat(4)2
Avg Revenue beat(4)2.21%
Min Revenue beat(4)-3.35%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.5%
Revenue beat(12)7
Avg Revenue beat(12)1.63%
Revenue beat(16)8
Avg Revenue beat(16)1%
PT rev (1m)-0.04%
PT rev (3m)41.21%
EPS NQ rev (1m)0.24%
EPS NQ rev (3m)17.25%
EPS NY rev (1m)0%
EPS NY rev (3m)10.31%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.44 | ||
| Fwd PE | 34.5 | ||
| P/S | 6.85 | ||
| P/FCF | 26.35 | ||
| P/OCF | 24.88 | ||
| P/B | 88.64 | ||
| P/tB | N/A | ||
| EV/EBITDA | 30.1 |
EPS(TTM)13.45
EY2.47%
EPS(NY)15.76
Fwd EY2.9%
FCF(TTM)20.64
FCFY3.8%
OCF(TTM)21.86
OCFY4.02%
SpS79.45
BVpS6.14
TBVpS-18.65
PEG (NY)2.99
PEG (5Y)1.22
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.61% | ||
| ROE | 242.7% | ||
| ROCE | 135.95% | ||
| ROIC | 115.03% | ||
| ROICexc | 132.51% | ||
| ROICexgc | N/A | ||
| OM | 21.4% | ||
| PM (TTM) | 18.74% | ||
| GM | 31.62% | ||
| FCFM | 25.98% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 118.36% | ||
| Cap/Sales | 1.54% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 121.25% | ||
| Profit Quality | 138.61% | ||
| Current Ratio | 0.43 | ||
| Quick Ratio | 0.43 | ||
| Altman-Z | 7.82 |
F-Score8
WACC10.47%
ROIC/WACC10.99
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)26.53%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%12.73%
EPS Next Y13.52%
EPS Next 2Y11.72%
EPS Next 3Y11.39%
EPS Next 5Y10.11%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%14.24%
Revenue Next Year16.85%
Revenue Next 2Y12.67%
Revenue Next 3Y11.46%
Revenue Next 5Y10.93%
EBIT growth 1Y25.19%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year22.27%
EBIT Next 3Y13.24%
EBIT Next 5Y12.21%
FCF growth 1Y55.28%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y50.59%
OCF growth 3Y32.23%
OCF growth 5Y24.7%